Logo.png
GRI Bio (NASDAQ: GRI) Announces FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant NKT (“iNKT”) Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)
November 27, 2023 08:35 ET | GRI Bio, Inc.
Clinical development plan leveraging 505(b)(2) regulatory pathway Initiation of Phase 2a biomarker study on track to start before year end Currently available treatments for IPF are limited to...
Logo.png
Idiopathic Pulmonary Fibrosis Market to Show Immense Growth at a CAGR of 6.6% During the Study Period (2019–2032) | DelveInsight
October 30, 2023 13:00 ET | DelveInsight Business Research LLP
New York, USA, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Idiopathic Pulmonary Fibrosis Market to Show Immense Growth at a CAGR of 6.6% During the Study Period (2019–2032) |  DelveInsight  The overall...
Logo.png
GRI Bio Presents Translational Data Demonstrating Connection Between NKT Cells and the Pathogenesis of Idiopathic Pulmonary Fibrosis (IPF) at the 2023 Pittsburgh-Ireland International Lung Conference
October 19, 2023 08:45 ET | GRI Bio, Inc.
Findings demonstrate that the number of NKT cells positively correlates with the number of airway macrophages in IPF patients GRI Bio on track to launch Phase 2a biomarker...
Kinarus-Logo_RGB.jpg
Kinarus Therapeutics Announces Personnel Change
July 12, 2023 01:00 ET | Kinarus Therapeutic Holding AG
Basel, Switzerland, July 12, 2023 – Kinarus Therapeutics Holding AG (“Kinarus”) (SIX: KNRS), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory and...
Kinarus-Logo_RGB.jpg
Kinarus Therapeutics Shareholders Approve All Board Proposals at the 2023 Annual General Meeting
June 29, 2023 12:00 ET | Kinarus Therapeutic Holding AG
Basel, Switzerland, 29 June 2023. Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus” or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral,...
Logo.png
GRI Bio (NASDAQ: GRI) Bolsters Patent Portfolio
June 27, 2023 08:45 ET | GRI Bio, Inc.
- U.S. patent issuance for lead program, GRI-0621, in development for the treatment of idiopathic pulmonary fibrosis (IPF) - Company building a robust global patent estate LA JOLLA, CA, June...
Logo.png
Ocean Biomedical, Inc. Joins the Russell 2000® Index
June 27, 2023 08:01 ET | Ocean Biomedical, Inc.
Ocean Biomedical’s Inclusion in the Russell 2000® Index and Russell 3000® Index Builds Momentum for Cutting Edge Therapeutic Programs Targeting Multiple Cancers, Fibrotic Diseases, and Malaria ...
Kinarus-Logo_RGB.jpg
Kinarus Therapeutics signed subordinated bridge loans to ensure further liquidity
June 27, 2023 01:00 ET | Kinarus Therapeutic Holding AG
Basel, Switzerland, June 26, 2023 – Kinarus Therapeutics Holding AG (“Kinarus”) (SIX: KNRS), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory and...
Avalyn Pharma Logo
Avalyn Pharma Highlighting Inhalation Platform at Upcoming H.C. Wainwright and Hanson Wade Conferences in June
June 15, 2023 08:00 ET | Avalyn Pharma Inc.
SEATTLE, June 15, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted therapies for life-threatening pulmonary diseases,...
Kinarus-Logo_RGB.jpg
Kinarus Therapeutics Publishes Invitation to the 2023 Annual General Meeting
June 02, 2023 01:00 ET | Kinarus Therapeutic Holding AG
Basel, Switzerland, 2 June 2023. Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus” or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral,...